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Learning objectives (3): 
- Optimal management of cardiac emergencies during pregnancy 
- Developing a delivery plan for pregnant women with an acute cardiac complication 
- To understand that the knowledge base is limited to expert opinion and experience, 
or observational cohort studies. There are no randomized trials.  
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Introduction 
Reducing maternal mortality was a major component of the fifth millennium development goal. A 
drop of 47%, was achieved mainly through reductions in sepsis and haemorrhage.[1] Maternal 
mortality due to cardiovascular causes has not decreased and in developed countries there even 
seems to be a tendency to increase.[2, 3] These women typically die due to cardiac emergencies like 
aortic dissection, acute coronary syndrome or heart failure.    
Pregnancy is characterised by a substantial haemodynamic challengeand hence, in women with 
known cardiac disease, the most common cardiovascular complication during pregnancy is heart 
failure.[4] In others, who present for instance with aortic dissection, a cardiac diagnosis may not have 
been known before. 
Preconception counselling by an experienced team of specialists is essential in order to estimate the 
risk of, and anticipate to, eventual cardiac complications in women with known cardiac disease. This 
is based on a combination of history, physical examination, VO2 max exercise testing, 
echocardiography and in some cases cardiac CT or MR. During counselling the potential implications 
of the cardiac condition on pregnancy outcome are also addressed. 
Careful evaluation of maternal risks can be based on several risk tools.[5-7] Of these, the modified 
World Health Organization (WHO) risk stratification model seems the best predictor of risks. Women 
in modified WHO class IV (a severely dilated aorta, pulmonary hypertension, severe systemic 
ventricular dysfunction, symptomatic left heart obstruction) are at such high risk of severe 
complications that they should be adviced against pregnancy.  
In women who present in pregnancy with a major cardiac event, early recognition of symptoms is 
important. Treatment is based on the underlying problem and prompt referral to a specialised center 
is strongly recommended. The maternal and fetal condition both determine further decisions in 
choosing a conservative or invasive approach. However, in life-threatening circumstances the mother 
always prevails. This strategy usually also serves in the best interest of the fetus. 
In this review, the most common acute cardiac complications during pregnancy are discussed. The 
incidence, diagnostics, and considerations regarding medication and intervention are outlined. A 
summary flow chart for practical use is provided for each complication. 
 
Heart failure  
Incidence and timing 
In two large prospective cohorts of pregnant women with cardiac disease, heart failure was the most 
common cardiac complication[4, 6] and in the largest study it was the most important reason of 
cardiac death.[8] The prevalence varies per cardiac condition. In a review of series and case reports, 
the occurrence of heart failure ranged from 4.8% in women with congenital heart disease in general, 
to more than 21.1% in patients with Eisenmenger disease.[9] In prospective studies of patients with 
any cardiac disease the prevalence is as high as 13.1%,[4] with highest prevalence in women with 
shunt lesions, diminished cardiac function and pulmonary hypertension (41%). Other patients at 
particular risk are those with a left heart obstruction.[10-13] [8, 14] [5, 15] [8] In patients with 
congenital heart disease and a baffle or conduit in situ, prosthesis related problems as an underlying 
cause should be ruled out. 
Heart failure typically occurs at the end of the second trimester or directly postpartum. At the end of 
the second trimester the cardiac adaptation with rise in cardiac output and plasma volume reaches 
its maximum[16], while uterine contractions are accompanied by brisk rises in cardiac output, and 
immediately postpartum a volume overload occurs by autotransfusion of the uteroplacental volume 
in the maternal circulation. These physiological mechanisms may explain the timing of heart failure, 
as summarised in Figure 1.[8, 16, 17] The timing of heart failure is different among the underlying 
cardiac diagnoses. While shunt lesions (atrial and ventricular septal defects) show a peak incidence of 
heart failure by the end of the second trimester, cardiomyopathies and stenotic lesions  more often 
manifest at the end of pregnancy and postpartum.[8] 
NT-proBNP is predictive of cardiovascular events during pregnancy, but is also elevated in pre-
eclamptic women without any cardiac abnormality, which is probably attributable to the pressure 
overload and cardiac dysfunction.[18-20] Therefore a low NT-proBNP has a high negative predictive 
value, but a high value does not have a high predictive value.There is a remarkable association 
between pre-eclampsia and heart failure. A study assessing cardiac function by cardiac ultrasound in 
patients with either preterm or term pre-eclampsia and normotensive controls showed signs of 
diastolic and systolic ventricular dysfunction mainly in women with preterm pre-eclampsia which is 
often the severe form.[21] Concurrently, 30% of cardiac patients suffering from pre-eclampsia, also 
developed heart failure during pregnancy.[8] Whether the (subclinical) cardiac dysfunction  is the 
cause, result or combination of both of defective adaptation and malplacentation leading to 
generalised endothelial dysfunction in severe early onset pre-eclampsia remains controversial and 
needs further investigation.[22, 23]   
Management (Figure 2) 
An experienced center from Germany published their management algorithm as used for patients 
with acute heart failure.[24] A multidisciplinary team gathers within 15 minutes after admission and 
decides on further management based on the maternal and fetal condition and prognosis. In case of 
a viable fetus, the choice of immediate delivery or continuing pregnancy with heart failure therapy 
according to the guidelines is based on parents wish and maternal and fetal condition.[5] In case of a 
non-viable fetus, maximum heart failure therapy is administered directly.   
In case of acute heart failure bedrest is advised. A few exceptions taken, pharmacological 
management of acute heart failure during pregnancy is according to the guidelines for treatment in 
non-pregnant patients.[25, 26] This should always be done in cooperation with the obstetrician. 
Diuretics can be given for congestive symptoms, and are considered safe during pregnancy.[27] 
Dosage should be increased with caution, to avoid intravascular volume depletion.  ACE inhibitors 
and angiotensin receptor blockers are contraindicated during the first, second and third trimester of 
pregnancy due to their fetotoxic effects[28] and can only be used in exceptional circumstances as 
stated by the FDA (category D). Instead, hydralazine and nitrates are considered as alternatives for 
afterload reduction.[29] Low dose beta-blockers can be considered in case of sinus-tachycardia or 
hypertension. Inotropic therapy can be considered in those who are continuously haemodynamically 
unstable: dopamine and levosimendan are then first choice agents, although evidence on efficacy 
and safety in pregnant women is limited and controversial.[5, 30, 31] In patients with ventricular 
dysfunction and consequently a cardiac thrombus or systemic emboli, therapeutic anticoagulation is 
recommended, preferably with either low molecular weight heparin or unfractionated heparin with 
adequate and strict monitoring of coagulation. Sinus rhythm should be aimed for in all patients with 
heart failure. Extensive information about cardiac medication has been given by the ESC guidelines 
on management of cardiovascular disease during pregnancy.[5] 
If the pharmacological treatment achieves stabilization of the maternal condition, a vaginal delivery 
is preferred as close as possible to term. A caesarean section does not seem to be protective or less 
strenuous for the cardiac condition in most women with cardiac disease.[32, 33] However, in 
individual cases CS might be considered, especially in those women with further deterioration in 
cardiac function, in whom is believed that the heart function is such that it may not cope with the 
strain of substantial fluctuations in cardiac output accompanying contractions during delivery.[5] 
Because of the large volume shifts shortly after delivery, women with a history of heart failure should 
still be monitored intensively for at least 48 hours after delivery. 
Heart failure in patients with pulmonary hypertension 
In patients with heart failure due to pulmonary arterial hypertension, in addition to treating the 
congestive symptoms, treatment with pulmonary vasodilators should be considered to lower the 
pulmonary pressure. Some of these agents have teratogenic effects, in particular endothelin receptor 
antagonists, and are contraindicated. Experience with the use of other advanced pulmonary arterial 
hypertension therapies during pregnancy is limited, but the use of prostanoid therapy and PDE5 
inhibitors in the current era seem to be associated with improved maternal survival during 
pregnancy.[34] Nitric oxide (NO) inhalation treatment may cause a fast decrease in pulmonary 
vascular resistance, and the use in parturients has been reported with a maternal survival of 68%, 
often administered as a final course of action.[35-37] A decision on mode of delivery in these women 
should be individualised. During caesarean section, the anaesthetic approach should include efforts 
to prevent major haemodynamic changes, and the use of oxytocin should be restricted. Systemic 
vascular resistance can be maintained by the use of low-dose phenylephrine or nor-adrenaline.[38] 
An experienced cardioaneasthesist is essential. 
Heart failure in patients with peripartum cardiomyopathy 
In women who present with congestive symptoms, a diminished left ventricular function and no 
history of a cardiac diagnosis in the last month of pregnancy or first months after delivery, 
peripartum cardiomyopathy should be considered as the underlying diagnosis. It is a diagnosis of 
exclusion and is probably related to dilated cardiomyopathy. Prolactin has been advocated to play an 
important role in the pathophysiology.[39, 40] Heart failure treatment is not different from the 
strategy in other pregnant patients, but in addition, bromocriptine is a promising agent. 
Bromocriptine is a dopamine-2D agonist that inhibits prolactin secretion, and in small studies it has 
shown to improve left ventricular function.[41, 42] Its efficacy is currently being investigated in a 
randomised controlled trial.[41]  
Arrhythmias   
Supraventricular tachycardia (Figure 3) 
Palpitations, but also dizziness and (near)syncope, may occur during normal pregnancy and are 
mostly benign: only 10% of symptomatic episodes are actually caused by arrhythmia.[43] In women 
with an arrhythmic event before pregnancy, recurrence rate of supraventricular arrhythmia during 
pregnancy is approximately 50%.[44] The occurrence of new onset symptomatic supraventricular 
tachycardia during pregnancy is rare. An incidence of 1.3% has been reported in women with cardiac 
disease. In pregnant women without cardiac history the incidence of supraventricular arrhythmia is 
presumably much lower, and mainly described in case reports and occurs often in the third 
trimester.[45] The workup in new onset atrial fibrillation is the same as outside pregnancy: after 
careful history and physical examination, an ECG, serum electrolytes and thyroid function, and an 
echocardiography should be performed to assess any possible predisposing or underlying 
abnormality. 
Guidelines recommend considering each antiarrhythmic agent as potentially fetotoxic.[5] Also, the 
physiological haemodynamic changes during pregnancy influence the pharmacokinetics of the 
agents, warranting dose adjustment in pregnant women. Like outside pregnancy, treatment depends 
on the maternal condition, duration of the arrhythmia and whether the hemodynamic condition is  
stable or not. The majority of suggested therapies is based on observational data. An extensive 
overview has been given by Tan and Lie in 2001.[46] Treatment recommendations are summarised in 
Figure 3. 
In case of an atrioventricular (nodal) re-entrant tachycardia, the first intervention is a vagal 
manoeuvre and if ineffective followed by adenosine. Both are reported to be safe in pregnancy.[47, 
48] Atrial tachycardia, including intra-atrial re-entry tachycardia, may also be treated with adenosine 
and if unsuccessful, a beta-blocker or digoxin can be started as rate control. Most beta-blockers are 
FDA category C, except for atenolol, which is marked as category D, and should be avoided.  
In atrial fibrillation, sotalol is considered FDA class B and can be used for rhythm control. Alternatives 
are intravenous ibutilide[49] or flecainide (FDA class C). In haemodynamic unstable patients or if 
pharmacological cardioversion failed, immediate direct current cardioversion should be performed, 
which is generally considered safe during pregnancy.  In any case, cardioversion should be done 
under strict fetal and maternal monitoring and with an obstetric team and facilities standby for 
immediate emergency caesarean section if necessary.[50] 
Agents that are not first choice treatment but can be considered because of their effectiveness 
outside pregnancy are: amiodarone (only short-term use, FDA D),[51] procainamide (FDA C, limited 
experience), propafenon (FDA C, limited experience), and verapamil (FDA C, risk of maternal 
hypotension and subsequent placental hypoperfusion). 
The indications for anticoagulant therapy are the same for pregnant women with supraventricular 
arrhythmias as for non-pregnant patients.[52] Pregnancy and the puerperium are a thrombogenic 
state and should be considered as an extra thromboembolic risk factor. Vitamin K antagonists (VKA, 
FDA category D) should preferably be stopped as soon as pregnancy is confirmed, because of the 
teratogenic risk, especially between weeks 6-9 and when high doses are needed.[53, 54] This can be 
replaced by (low molecular weight) heparin (LMWH, FDA category B) . There is hardly any evidence 
on the safety of new oral anticoagulation (NOAC) therapy during pregnancy. In rats, most of the 
NOACs cross the placenta, and therefore NOACs should not be used, although short-term use of 
rivaroxaban in the first trimester did not reveal severe problems in the short term.[55]  
 
Ventricular tachycardia 
Although ventricular arrhythmia’s are probably even rarer than supraventricular tachycardia’s, they 
are potentially associated with more detrimental consequences. The incidence of ventricular 
tachycardia in women with cardiac disease is approximately 1.0-1.4%.[6, 56] The influence of 
pregnancy on catecholamine levels might play a role in the pathophysiological mechanism. These 
catecholamine induced tachycardia’s appeared sensitive to beta-blockers.[57] In channelopathies 
such as Brugada syndrome, the trigger seems to be more hormone related.[58] A ventricular 
arrhythmia in the third trimester or postpartum period in previously healthy women, may also be the 
first presentation of peripartum cardiomyopathy.[59, 60] A remarkable reduced risk of events in long 
QT syndrome has been observed during the course of pregnancy, whilst the postpartum period 
seems to be associated with an increased risk.[61] [62] [63]   
In all patients the main target of treatment is to retrieve or maintain haemodynamic stability, for the 
benefit of the mother, and by doing so also for the fetus. In a haemodynamically unstable patient 
with any type of ventricular tachycardia, immediate defibrillation is indicated.[64] If a patient is 
stable, chemical cardioversion can be considered. First choice drug in women who have a 
monomorphic ventricular tachycardia, without signs of long-QT syndrome, is IV sotalol (FDA B) or 
procainamide (FDA C).[65] In case of sustained refractory or recurrent ventricular tachyarrhythmias, 
not directly responding to defibrillation, IV amiodarone is an alternative . 
In patients with idiopathic right ventricular outflow tract tachycardia, which is probably the most 
common ventricular arrhythmia in otherwise healthy pregnant women, verapamil or beta-blockers 
are usually effective[46] to prevent recurrent episodes. Therapeutic management of ventricular 
arrhythmias is further summarised in Figure 4.[66, 67] 
In patients with poorly tolerated and drug resistant tachyarrhythmia’s, radio frequency ablation can 
be considered. Evidence on safety during pregnancy is lacking and based on case reports. General 
advice is to perform ablation in the second trimester if possible and with ultrasound assistance, to 
minimise the potential influence of radiation on fetal organogenesis.[64, 68] Limited experience with 
an implantable cardioverter-defibrillator (ICD) during pregnancy revealed no major problems.[69-71] 
Reports of experience with ICD implantation during pregnancy are lacking, but a subcutaneous ICD is 
a promising technique as fluoroscopy is no longer required.[64] 
 
Resuscitation 
Several guidelines provide practical advices concerning the treatment of maternal cardiac arrest, 
which are summarised in Table 1. [72, 73]  
Immediate basic life support and, when available, advanced life support should be initiated as in non-
pregnant persons. In order to make chest compressions effective it is important to relieve aortocaval 
compression once pregnancy has progressed beyond 20 weeks by left lateral manual displacement of 
the gravid uterus or by putting a wedge under her right side. If resuscitation is not successful by 4 
minutes, emergency perimortem caesarean section is advised on site and delivery achieved within 
the minute on maternal indication. The main aim of this procedure is to increase the chances of 
successful resuscitation by effectively relieving aortocaval compression and creating a sudden 
autotransfusion with the blood that was stored in the uteroplacental circulation. As an additional 
benefit it increases fetal survival as the uteroplacental perfusion is poor during arrest and chest 
compressions.[74, 75] The uterus is considered a non-essential organ and not perfused. 
The position of chest compressions has been recently studied. The authors stated that the previously 
suggested higher sternal position of the hands during pregnancy is based on the presumption that 
the maternal heart is positioned superiorly in the third trimester.[76] However, an MRI in 34 
pregnant females, showed no significant displacement of the heart. Therefore, there is no need to 
adjust the hand position. The outcome of cardiopulmonary resuscitation during pregnancy has been 
described by a population-based cohort study from Canada. The authors reported a survival of 
36.9%, which was better than the survival in matched non-pregnant women.[77] 
 
Acute Myocardial Infarction  
An acute myocardial infarction (AMI) occurs 3 to 4 times more often during pregnancy than in non-
pregnant women of the same age.[78] The incidence ranges in population-based studies from 
1:35,700 [79] to a more recent estimation of 1:17,000 [78] with a maternal mortality rate of 5-7%. 
.[80] [81, 82] At highest risk of AMI are pregnant women of older age, in particular those >40 years, 
women with a history of pre-eclampsia and women with  cardiovascular risk factors, such as smoking 
and diabetes.[78, 79] Patients with known ischemic heart disease have a 10% risk of a cardiac event 
(cardiac arrest, heart failure, acute coronary syndrome, or ventricular arrhythmia) in a subsequent 
pregnancy.[83] 
Diagnostics 
The first presentation of an acute myocardial infarction may be a cardiogenic shock (38%) or with a 
ventricular arrhythmia (12%).[80] First assessment of patients suspected for an acute coronary 
syndrome should be similar as in non-pregnant patients. Time to intervention is as important in 
pregnant women with an ST-elevation myocardial infarction (STEMI) as in non-pregnant patients, and 
therefore, an ECG should be made directly. Cardiac markers may also reveal the diagnosis, whether 
or not supported by echocardiography to investigate wall motion abnormalities. Troponin I is 
generally not influenced by pregnancy or pre-eclampsia and therefore an elevated level is highly 
suspicious of an AMI.[84-86] Imaging of the underlying coronary anatomy is key in the further 
therapeutic approach of a STEMI. An urgent coronary angiography should therefore be performed 
and is not associated with high rates of fetal radiation exposure, but iatrogenic dissections have been 
reported. The most common diagnosis is an acute coronary dissection.[87] In a review of literature 
between 2006 and 2011, the angiogram showed: coronary dissection in 43% (mainly postpartum); 
atherosclerosis in 27%; coronary thrombus in 17% (both mainly in second or third trimester); normal 
in 9%; vasospasm in 2%; tako tsubo in 2% (postpartum) of AMI.[80] Because of the risk of dissection 
induction, a non-invasive approach has been advocated as an alternative in stable and low-risk 
women with a Non-ST-elevation myocardial infarction. 
 
Treatment of myocardial infarction 
Treatment of pregnant women with an AMI depends on the aetiology and is further delineated in 
Figure 5. In case of a coronary dissection, thrombolysis should be avoided because of the local 
bleeding risks which might worsen the situation.[80] [88] [89] Percutaneous coronary intervention 
(PCI) is the first choice of therapy, as it is in case of atherosclerosis. A PCI does induce fetal radiation 
exposure, but even in difficult procedures the potential benefits outweigh the risks.[90] If possible, 
balloon angioplasty may be considered, because knowledge on antiplatelet therapy such as 
clopidogrel in pregnancy is limited(FDA class B). The use of low dose aspirin is safe. There is a lack of 
experience with Glycoprotein IIb/IIIa during pregnancy, and thus it should be avoided. Nitrates are 
widely used in pregnant women for tocolysis and have proven to be safe.[91] Nifedipine is the 
calcium antagonist that has been used most frequently during pregnancy for hypertension and 
tocolysis[92] and is the drug of choice in women with vasospasm associated complaints. Statins are 
contraindicated during pregnancy (FDA class X).  
Coronary artery bypass grafting (CABG) is associated with high fetal loss, and should preferably be 
performed after delivery if the fetus is viable. Cardiac surgery during pregnancy has mainly been 
reported in valvular or aortic disease while CABG experience consists of case reports only.[81] When 
unavoidable, the second trimester is probably the safest period, and surgery is best performed in left 
lateral position in normothermic condition with high pump flow.  
In patients with a coronary thrombus, thrombolysis may be considered. The available evidence of 
thrombolysis during pregnancy for myocardial infarction is limited,[88] and is mainly based on the 
use of recombinant tissue plasminogen activator. Most experience during pregnancy for other 
reasons than AMI, concerns the use of streptokinase.[89] 
After the course of a successfully treated ischemic event during pregnancy, the preferred mode of 
delivery is vaginal, with caesarean section reserved for obstetric reasons.[93, 94]  
 
Aortic dissection  
Incidence  
Pregnancy induces not only haemodynamic changes, but also influences the integrity of the vessel 
wall. A morphological study showed marked fragmentation of reticular fibres in the tunica media of 
the aorta in pregnant women without aortic disease.[95] Also, smooth muscle cells in the aortic 
media were subject to both hypertrophy and hyperplasia, compared to non-pregnant women. These 
adaptations are usually well tolerated by healthy women: the incidence of aortic dissection in 
women of reproductive age is low (0.4 per 100,000 person years).[96] But women with aortic disease 
are at increased risk of aortic dilatation and aortic dissection. It is the most important cause of 
cardiac maternal death in the UK.[2]  
At high risk are women with Marfan syndrome, an autosomal dominant connective tissue disease, 
with a reported rate of pregnancy-related aortic dissection of up to 4.5% in prospective studies,[97-
99] and up to 6.4% in retrospective studies.[100-104] Other diseases that need careful preconception 
counselling and follow-up, are women with Loeys-Dietz,[105] vascular type Ehlers Danlos,[106] 
SMAD3 mutation or Aneurysm Osteoarthritis Syndrome,[107, 108] ACTA2 mutation,[109] TGFB3 
mutation,[110] unspecified familial thoracic aortic aneurysm and dissection syndrome, Turner 
syndrome[111, 112] and bicuspid aortic valve.[113] Studies reporting vascular complications during 
pregnancy in these women are scarce and small; the largest studies included mainly women with 
Marfan syndrome. Important and independent risk factors are initial aortic size and rate of diameter 
change during pregnancy.[104] [5]  
 
Management of type A aortic dissection (Figure 6) 
As mortality due to aortic dissection remains high,[114] each symptomatic pregnant patient with 
known aortic disease or with signs or symptoms suspected of aortic dissection should be 
immediately evaluated in order to rule out aortic dissection. Echocardiography should be done 
promptly, if needed followed by computed tomography. Although MRI is preferred to avoid radiation 
exposure of the fetus, CT is performed much faster in the acute situation of a suspected aortic 
dissection and may be the method of choice in the acute setting. If aortic dissection is diagnosed, a 
patient should be treated similar as advised outside pregnancy. An extensive outline of management 
of aortic dissection has been reported in 2014.[115] The number of recommendations about aortic 
dissection during pregnancy is limited, probably due to lack of evidence. Type A aortic dissection 
warrants emergency aortic surgery. Whether this should be performed before, together with or after 
delivery depends on the viability of the fetus and the local situation (Figure 6).[116] A high 
intraoperative fetal mortality rate has been reported in many case reports and series, indicating that 
delivery before surgery in case of a viable fetus is preferable.[5] 
 
Management of type B aortic dissection (Figure 6) 
The guidelines recommend conservative management in type B aortic dissections. Strict blood 
pressure regulation is warranted, with bedrest up to delivery. Fetal demise is reported to be as high 
as 35%, probably due to compromised uterine and placental perfusion.[117, 118] Frequent 
monitoring of the aortic status by MRI should be done during follow-up.  
An alternative approach in complicated dissections of the descending aorta is an endovascular 
procedure (TEVAR). A few studies have reported favourable outcomes, some in acute type B aortic 
dissection.[119] Recently, a successful result with an endograft during pregnancy as bridge to open 
repair was presented.[120] More studies are warranted to determine further the safety and efficacy 
of this approach is pregnant women.  
 
Although the role of beta-blockers in prevention of aortic dissection is equivocal, the benefit of use in 
patients with aortic dissection is clearer. In the IRAD study, beta-blockers were associated with 
better survival mainly after type A aortic dissections.[121] First choice are labetalol or metoprolol. 
Labetalol combines alfa and beta blocking properties and as such also reduces vascular resistance. 
During pregnancy, beta-blockers can be administered safely, with close monitoring of the fetus, as it 
may result in a lower birth weight.[122] Angiotensin receptor blockers and ACE inhibitors are 
contraindicated because of reported toxic effects on the fetal kidneys and bone malformations.[123] 
Hydralazine might be used instead, or on top of beta-blockers. However one should be cautious as 
hydralazine can induce brisk arterial relaxation with uteroplacental hypoperfusion. [125] Calcium 
channel inhibitors seem to exacerbate aneurysm growth, in a mouse model outside pregnancy,[124] 
and are therefore not first choice. Methyldopa, being first choice of treatment for gestational 
hypertension, might be administered as well, although there is little to no evidence on its use in 
women with aortic dissection.   
 
Mechanical valve thrombosis  
Incidence  
Pregnancy is a hypercoagulable state, with decrease of anticoagulants such as protein S, and increase 
of coagulation factors and level of fibrinogen.[126, 127] The risk of mechanical valve thrombosis is 
obviously increased, and can lead to a catastrophic outcome of both mother and child. Several 
studies reported on the incidence of valve thrombosis, varying from 3.7% to 9.4%.[128-134] At high 
risk are women with a mechanical valve in mitral or tricuspid position, or low flow due to ventricular 
dysfunction.[135] Also, sub therapeutic treatment poses a patient to an increased risk.[136] 
Therefore, switching anticoagulant agents in the first trimester and peripartum period is presumably 
associated with a high-risk. This is however, difficult to confirm, becauseof the limitednumber of 
studies with low numbers of events.  
Diagnostics and Management (Figure 7) 
In every pregnant patient with a mechanical valve prosthesis who presents with complaints of 
dyspnea, fatigue, palpitations, signs of heart failure, soft or absent prosthetic valve sounds or a 
systemic emboli, valve thrombosis should be suspected and ruled out.[136, 137] A transthoracic 
echocardiography is the first step towards diagnosis. If the diagnosis cannot be confirmed, and/or 
the patient is haemodynamically stable, a transoesophageal echocardiography (TOE) provides images 
at higher resolution with better views on the atrial edge and the ability to accurately determine the 
thrombus size, which is predictive of embolic risk.[138] If the diagnosis is still not clear, fluoroscopy 
might provide more insight with little radiation exposure to the fetus.[90, 136] 
In haemodynamically unstable patients and obstructive thrombosis, emergency surgery is first choice 
treatment, preceded by caesarean section if the fetus is viable.[139] In case of a haemodynamically 
stable woman, different strategies are available, broadly in line with the approach of non-pregnant 
patients. Oral anticoagulant therapy or heparin may be continued and optimised in patients with a 
recent sub therapeutic INR, APTT or anti-Xa level, and non-obstructive left sided valve thrombosis.[5, 
140] In other patients thrombolysis or surgery should be discussed and weighed. Outside pregnancy, 
thrombolysis as first choice seems to be beneficial opposed to surgery.[141, 142] However, 
randomised controlled trials are not yet available,[140] and the suggested estimated sample size of 
future studies will be hard to achieve.[141] 
Fibrinolytic therapy does not or limitedly cross the placenta, but experience during human pregnancy 
is insufficient, in particular in women with a mechanical valve. Main concern is that fibrinolysis may 
cause systemic emboli, and hence, it should be avoided in patients with large and mobile thrombi, a 
left atrial thrombus as determined by TOE,[137, 143] or with a recent systemic emboli. Outside 
pregnancy, thrombolysis has shown to be an effective therapy, with high success rate in selected 
patients.[144] In patients with a right-sided valve thrombosis or when surgery is not directly available 
in the severely ill patient, it is the first choice therapy.[139] One study reported 24 consecutive 
women (2004-2012) with valve thrombosis during pregnancy, treated with a specific thrombolysis 
protocol, and showed reassuring results.[137] Patients were treated with slow infusion of low dose 
tissue plasminogen activator (t-PA, 25 mg) in 6 hours, which was repeated up to 6 times, with a 
maximum dose of 150mg. Treatment was given under guidance of serial TOE, which is also current 
practice outside pregnancy.[143, 145, 146] Complete thrombus lysis was reached in all and no 
maternal mortality was observed. Five early pregnancies resulted in miscarriage, 1 to 5 weeks after 
thrombolytic therapy. The results of this study are encouraging, but the authors also emphasise that 
these treatment options are complementary: high-risk patients or those with a contraindication to or 
failure of thrombolysis, should still be considered for surgical therapy. In addition, a delivery in a 
woman with recent thrombolysis is very unattractive. 
Surgical valve replacement or thrombectomy is preferred in patients with obstructive thrombosis 
and those who are critically ill.[139] Also large and mobile thrombi may be considered for direct 
surgery.[147] However, surgery is associated with a high rate of fetal mortality and morbidity,[148] 
although outcomes seem to have improved over time.[149, 150] Fetal demise occurs often when 
surgery is performed prior to delivery, with reported fetal mortality rates of 20-30%,[149-151] which 
is why delivery of a viable fetus should be performed prior to surgery. During surgery, physiological 
changes of pregnancy are accompanied by haemodilution, changes in coagulation and hypotension 
induced by cardiopulmonary bypass. Uteroplacental hypoperfusion is the reason for the high rate of 
fetal demise.[152] It has been suggested that normothermic surgery might bear lower risks than 
hypothermia.[153] Surgery should be performed in left lateral position and a higher pump flow is 
desired to maintain placental perfusion. 
Summary 
A multidisciplinary high-risk team should evaluate women suffering from cardiovascular 
emergencies, or those at high risk. Acute cardiovascular complications are potentially devastating 
events if not recognised early and treated by experienced specialists. Decisions concerning 
intervention and a delivery plan need to be made on an individual basis and often do not differ much 
from treatment outside pregnancy. Large studies investigating cardiac treatment for emergencies in 
pregnant women are lacking, and hence, therapeutic strategies are mainly based on expert opinion 
and small observational studies. Risks and benefits for both mother and child need to be outweighed, 
with a clear preference of at least maintaining a maternal haemodynamically stable situation.   
Key points 
• Treating pregnant women for a cardiac event means that there are two lives to save. 
Generally, a patient should get the same approach as a non-pregnant patient. If the fetus is 
viable, an urgent delivery is preferred, if safer for the mother, which expands further 
treatment options of the mother and reduces the cardiac burden. 
• Heart failure is the most common complication during pregnancy; strong independent 
predictors before pregnancy are a diagnosis of cardiomyopathy and a WHO class 3 or 4. Signs 
of heart failure should be treated well before potential conception. Except for ACE inhibitors 
and angiotensin receptor blockers which are contraindicated, heart failure treatment is not 
different from outside pregnancy. 
• The main aim of treating arrythmias is to retrieve or maintain a haemodynamically stable 
situation. Immediate defibrillation is therefore indicated in any unstable patients. The 
majority of antiarrhythmic drugs should be considered as fetotoxic, but a lifethreatening 
maternal event does justify their use in the acute setting.  
• In case of a maternal cardiac arrest with no success after four minutes, emergency caesarean 
section is indicated. 
• Acute myocardial infarction is a potential catastrophic event and in case of a STEMI the first 
aim is to urgently reveal the underlying coronary anatomy, as this has therapeutic 
implications. A coronary dissection is the most common cause, which is a contraindication 
for thrombolysis.  
• Acute aortic dissection should be treated following the guidelines of treatment in non-
pregnant patient. In Type A dissection, an individualised decision should be made on 
whether the baby is delivered first by emergency caesarean section before aortic surgery is 
done. 
• When a mechanical valve thrombosis during pregnancy has been diagnosed, thrombolysis 
may be considered in the same patients that would be a candidate outside pregnancy: in 
patients with right-sided prosthesis, patients who recently had subtherapeutic 
anticoagulation and non-critical ill patients. Emergency surgical replacement, preferably 
directly after caesarean section, is preserved for left-sided lesions and severely symptomatic 
patients. 
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Figure 2 Management of pregnant patients with acute heart failure 
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Figure 7 Management of mechanical valve thrombosis during pregnancy 
 
 
 
  
 
